A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
The following discussion of our business contains forward-looking statements that involve risks and uncertainties (see the section entitled “Forward-Looking Statements” herein). Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those factors set forth under “Risk Factors” and elsewhere in this Form 10-K. We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, and distribution.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 96M | 96M | 75M | 76M | 162M | 119M |
| Net Income | -4.6M | -4.6M | -20M | -68M | -140M | -8.9M |
| EPS | $-0.10 | $-0.10 | $-0.44 | $-1.55 | $-3.29 | $-0.23 |
| Free Cash Flow | 11M | 11M | 5.2M | -19M | -19M | -13M |
| ROIC | -3.6% | -1.3% | -1.5% | -19.1% | -36.0% | -1.8% |
| Gross Margin | 64.6% | 64.6% | 67.1% | 65.0% | 45.3% | 41.5% |
| Debt/Equity | 0.06 | 0.06 | 0.12 | 0.12 | 0.12 | 0.06 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -17M | -17M | -4.5M | -71M | -146M | -35M |
| Operating Margin | -17.3% | -17.3% | -6.0% | -93.4% | -90.0% | -29.5% |
| ROE | -1.2% | -1.3% | -5.8% | -20.1% | -38.4% | -1.9% |
| Shares Outstanding | 46M | 46M | 46M | 44M | 42M | 39M |
BIOLIFE SOLUTIONS INC passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 56.7%.
BIOLIFE SOLUTIONS INC (BLFS) has a 5-year average return on invested capital (ROIC) of -12.0%. This is below average and may indicate limited pricing power.
BIOLIFE SOLUTIONS INC (BLFS) has a market capitalization of $931M. It is classified as a small-cap stock.
BIOLIFE SOLUTIONS INC (BLFS) does not currently pay a regular dividend.
BIOLIFE SOLUTIONS INC (BLFS) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
BIOLIFE SOLUTIONS INC (BLFS) reported annual revenue of $96 million in its most recent fiscal year, based on SEC EDGAR filings.
BIOLIFE SOLUTIONS INC (BLFS) has a net profit margin of -4.8%. The company is currently unprofitable.
BIOLIFE SOLUTIONS INC (BLFS) generated $11 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BIOLIFE SOLUTIONS INC (BLFS) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
BIOLIFE SOLUTIONS INC (BLFS) reported earnings per share (EPS) of $-0.10 in its most recent fiscal year.
BIOLIFE SOLUTIONS INC (BLFS) has a return on equity (ROE) of -1.3%. A negative ROE may indicate losses or negative equity.
BIOLIFE SOLUTIONS INC (BLFS) has a 5-year average gross margin of 56.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for BIOLIFE SOLUTIONS INC (BLFS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BIOLIFE SOLUTIONS INC (BLFS) has a book value per share of $8.09, based on its most recent annual SEC filing.